Drug Approvals International – Page 117 – All about Drugs Live by Dr Anthony Melvin Crasto

Biocon Launches KRABEVA® in India, A Biosimilar Bevacizumab for Treating Several Types of Cancer

Biocon Launches KRABEVA® in India, A Biosimilar Bevacizumab for Treating Several Types of Cancer On November 23, 2017, Biocon India’s premier Biopharmaceuticals Company announced that it has launched KRABEVA®, a biosimilar Bevacizumab for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian and brain cancers, in India 1. KRABEVA®, a monoclonal …

Pexidartinib, New Patent, WO 2017215521, Crystal Pharmatech Co Ltd

Pexidartinib, New Patent, WO, 2017215521, Crystal Pharmatech Co Ltd (WO2017215521) PLX3397 HYDROCHLORIDE CRYSTAL FORM, PREPARATION METHOD THEREFOR AND USE THEREOF https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017215521 CRYSTAL PHARMACEUTICAL (SUZHOU) CO., LTD INVENTORS CHEN, Minhua; (CN). ZHANG, Yanfeng; (CN). ZOU, Po; (CN). ZHANG, Xiaoyu; (CN) Novel crystalline forms of PLX3397 hydrochloride (designated as Forms CS2 and CS3), processes for their preparation …

Psilocybin, псилоцибин , بسيلوسيبين , 赛洛西宾 ,

Psilocybin Molecular FormulaC12H17N2O4P Average mass284.248 Da 4-22-00-05665 (Beilstein Handbook Reference) [Beilstein] 520-52-5 [RN] 1H-Indol-4-ol, 3-[2-(dimethylamino)ethyl]-, dihydrogen phosphate (ester) 208-294-4 [EINECS] 3-[2-(Dimethylamino)ethyl]-1H-indol-4-ol Dihydrogen Phosphate Ester псилоцибин [Russian] [INN] بسيلوسيبين [Arabic] [INN] 赛洛西宾 [Chinese] [INN] NM 3150000 O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine P-7825 PDSP1_001391 UNII-2RV7212BP0 MP 220-228 deg C, O’Neil, M.J. (ed.). The Merck Index – An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th Edition, Whitehouse Station, …

ALCAFTADINE, WO 2017211246, NEW PATENT, SHENZHEN TARGETRX, INC.

Alcaftadine NEW PATENT https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017211246&redirectedID=true WO-2017211246, SHENZHEN TARGETRX, INC. SUBSTITUTED FUSED IMIDAZOLE CYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF WANG, Yihan; (CN). XING, Qingfeng; (CN) Novel deuterated analogs of substituted fused imidazole cyclic compounds, particularly alcaftadine are histamine H1-receptor antagonists and mast cell stabilizers, useful for treating allergy and nasal congestion. The present invention relates to a substituted …

Benzyl (5-methylpyrazin-2-yl)carbamate

2-(Cbz-Amino)-5-methylpyrazine Molecular Formula: C13H13N3O2 Molecular Weight: 243.266 g/mol Benzyl (5-methylpyrazin-2-yl)carbamate CAS 1033418-57-3 Mp 191.4 °C. IR 1719, 1567, 1353, 1226, 1054, 759, 744, 706 cm–1. 1H NMR (DMSO-d6, 500 MHz) 10.45 (br, 1H), 8.93 (s, 1H), 8.20 (s, 1H), 7.42–7.32 (m, 5H), 5.18 (s, 2H), 2.41 (s, 3H). 13C NMR (DMSO-d6, 125.7 MHz) 153.6, 147.7, 146.7, …

FDA approves first drug for Eosinophilic Granulomatosis with Polyangiitis, a rare disease formerly known as the Churg-Strauss Syndrome

FDA approves first drug for Eosinophilic Granulomatosis with Polyangiitis, a rare disease formerly known as the Churg-Strauss Syndrome The U.S. Food and Drug Administration today expanded the approved use of Nucala (mepolizumab) to treat adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease that causes vasculitis, an inflammation in the wall of …

Gedatolisib, гедатолисиб , غيداتوليسيب , 吉达利塞 ,

Gedatolisib Pfizer PF-05212384; PF-5212384; PKI-587 CAS 1197160-78-3 Chemical Formula: C32H41N9O4 Molecular Weight: 615.72 1-(4-{[4-(Dimethylamino)-1-piperidinyl]carbonyl}phenyl)-3-{4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl}urea 3-{4-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl}-1-{4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl}urea N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N‘-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea гедатолисиб [Russian] [INN] غيداتوليسيب [Arabic] [INN] 吉达利塞 [Chinese] [INN] Phase III Acute myeloid leukaemia Phase II Colorectal cancer; Non-small cell lung cancer Phase I Breast cancer; Solid tumours Discontinued Endometrial cancer Most Recent Events 22 Nov 2017Pfizer suspends patient enrolment in a phase I/II trial due to drug supply …

FDA approves Admelog, the first short-acting “follow-on” insulin product to treat diabetes

FDA approves Admelog, the first short-acting “follow-on” insulin product to treat diabetes The U.S. Food and Drug Administration today approved Admelog (insulin lispro injection), a short-acting insulin indicated to improve control in blood sugar levels in adults and pediatric patients aged 3 years and older with type 1 diabetes mellitus and adults with type …

FEVIPIPRANT

FEVIPIPRANT Molecular Formula: C19H17F3N2O4S Molecular Weight: 426.41 g/mol UNII-2PEX5N7DQ4; 2PEX5N7DQ4; NVP-QAW039; QAW039; CAS 872365-14-5 Product patent WO2005123731A2, NOVARTIS Inventors Kamlesh Bala, Catherine Leblanc, David Andrew Sandham, Katharine Louise Turner, Simon James Watson, Lyndon Nigel Brown, Brian Cox, Less « Applicant Novartis Ag, Novartis Pharma Gmbh Jun 17, 2004 priority expiry 2014 SYN 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-b]pyridin-3-yl]acetic acid 2-Methyl-1-[[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl]methyl]-1H-pyrrolo[2,3-b]pyridine-3-acetic acid [1-(4-((Methane)sulfonyl)-2-trifluoromethylbenzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]acetic acid Fevipiprant (INN; code name QAW039) is a drug being developed …

Hypericin

Hypericin Hypericin is a naphthodianthrone, an anthraquinone derivative which, together with hyperforin, is one of the principal active constituents of Hypericum (Saint John’s wort).[2][3] Hypericin is believed to act as an antibiotic, antiviral[2] and non-specific kinaseinhibitor. Hypericin may inhibit the action of the enzyme dopamine β-hydroxylase, leading to increased dopamine levels, although thus possibly decreasing norepinephrine and epinephrine. It was initially believed that the anti-depressant pharmacological activity of hypericin was due …